FORM 4

obligations may continue. See

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vvasnington, i	D.C.	20549	
----------------	------	-------	--

STATEME

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Eldridge George A						Aerovate Therapeutics, Inc. [AVTE]									all applie Directo Officer	tor er (give title		10% Ov Other (s	vner		
(Last) (First) (Middle) C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500						3. Date of Earliest Transaction (Month/Day/Year) 11/30/2022									SEE REMARKS						
(Street) WALTH			02451 (Zip)		4. If	f Amen	dment	t, Date	e of Orig	inal F	iled (Month/D		Indivine)	′							
		Tabl	e I - I	Non-Deriv	/ative	Sec	uritie	es A	cquire	ed, D)isposed (of, or E	enefici	ally (Owned	t					
Date				2. Transacti Date (Month/Day	.	Execu rear) if any		Deemed ecution Date, any onth/Day/Year)		ction Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an)		es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price			ported nsaction(s) str. 3 and 4)					
Common Stock 11/30/202)22	22			M ⁽¹⁾		85	Α	\$2.14		2,045			D			
Common	ommon Stock 11/30/202)22	22		S ⁽¹⁾		85	D	\$19.060	9.0604(2)		1,960		D				
		Т	able								sposed of s, converti				wned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	tion Date,	4. Transa Code (8)				6. Date Exerc Expiration Di (Month/Day/\)		ate	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		De Sed (Ins	Price of erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amoun or Numbe of Shares								
Stock Option (Right to	\$2.14	11/30/2022			M ⁽¹⁾			85	(3)	04/01/2031	Commo	n 85		\$0	96,293		D			

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$19.00 to \$19.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- $3.\ A$ total of 98,676 shares subject to an employee stock option were granted on April 1,2021, with 25% of this option vested on June 4,2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: Chief Financial Officer and Treasurer

/s/ George A. Eldridge 12/02/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.